Angiogenesis, Exudation, and Degeneration February 6, 2016 Mandarin Oriental, Miami, FL

Transcription

1 Angiogenesis, Exudation, and Degeneration 2016 February 6, 2016 Mandarin Oriental, Miami, FL Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD Course Associate Director: Carmen A. Puliafito, MD, MBA PROGRAM Subject to Change Saturday, February 6, :00 am Registration and Continental Breakfast 7:55 Welcome and Overview Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA Session I: Top Innovations in Retina 8:00 Top Innovations in Retina A VC s Perspective? Emmett T. Cunningham, Jr., MD, PhD, MPH 8:10 OCT Angiography Where We Stand in 2016 Jay S. Duker, MD Session II: Imaging of Retinovascular Diseases 8:20 Diabetic Maculopathy Grading Using OCT Angiographic Capillary Perfusion Mapping Andre Romano, MD 8:30 Volume Rendered Angiographic and Structural Optical Coherence Tomography of Diabetic Retinopathy Richard F. Spaide, MD

2 8:40 Automated Segmentation and Quantification of Angiographic Features on Ultra- Widefield Fluorescein Angiography Justis P. Ehlers, MD 8:50 Does Wide-field Guided Pan-retinal Ablation Decrease the Treatment Burden of Anti-VEGF Management of DME? David M. Brown, MD, FACS 9:00 DRCR.net Update Harry W. Flynn, Jr., MD Session III: Retinovascular Diseases Moderator: Harry W. Flynn, Jr, MD 9:10 Update on Ranibizumab for Diabetic Retinopathy from the Ride and Rise Studies David S. Boyer, MD 9:20 Update on Aflibercept for DME Diana V. Do, MD 9:30 Aflibercept for Recalcitrant DME Elias Reichel, MD 9:40 Pharmacotherapy in Development for Diabetic Macular Edema Quan Dong Nguyen, MD, MSc 9:50 Update on the MacTel Project Martin Friedlander, MD, PhD 10:00 Update on AZOOR Lawrence A. Yannuzzi, MD Session IV: Age-Related Macular Degeneration I Moderator: Philip J. Rosenfeld, MD, PhD 10:10 Evidence for Mitochondrial Dysfunction in AMD Pathology Deborah Ferrington, PhD 10:20 Photoreceptor Energy Needs and Angiogenesis in AMD Lois Smith, MD, PhD

3 10:30 Reticular Macular Disease, the Choroid, and Cardiovascular Disease Theodore Smith, MD 10:40 OCT Angiography in Dry Age Related Macular Degeneration Nadia Waheed, MD 10:50 Neovascular Intermediate AMD: A New Stage of Non-Exudative AMD Luiz Roisman, MD 11:00 Differential Diagnosis of Macular Atrophy: An Angio OCT Study Giovanni Staurenghi, MD Session V: Age-Related Macular Degeneration II 11:10 Update from the Classification of Atrophy Meeting I SriniVas R. Sadda, MD 11:20 Update from the Classification of Atrophy Meeting II Frank Holz, MD 11:30 Nascent GA Detected with En Face OCT Imaging Karen B. Schaal, MD 11:40 Automated Choroidal Thickness Measurements from Widefield OCT Fang Zheng, MD 11:50 Peripheral Retinal Changes Associated with AMD on Widefield Fundus Photography Emily Y. Chew, MD Session VI: AMD: Emerging Therapies and Ongoing Clinical Trials Moderator: Philip J. Rosenfeld, MD, PhD 12:00 pm Preclinical Efficacy of MTP-131, a Mitochondrial Targeting Drug, in Mouse Models for Dry AMD Scott W. Cousins, MD 12:10 Modified Nucleoside Reverse Transcriptase Inhibitor for Atrophic and Neovascular AMD Jayakrishna Ambati, MD

4 12:20 Emixustat Update Lukas Scheibler, PhD 12:30 Lampalizumab Update Brandon Busbee, MD 12:40 Complement C5 Inhibition for AMD Parisa Zamiri, MD, PhD 12:50 Complement C3 Inhibition in AMD Cedric Francois, MD 1:00 Non-Damaging Laser Therapy of the Macula: Mechanisms and Applications Daniel Palanker, PhD 1:10 Lunch Session VII: Macular Neovascularization and Imaging 2:00 Efficacy and Safety of Conbercept Ophthalmic Injection in Treatment of Choroidal Neovascularization Secondary to Pathological Myopia (Shiny Trial) Youxin Chen, MD 2:10 Imaging-histology Correlations in Pigment Epithelium Detachment Christine A. Curcio, PhD, FARVO 2:20 Widefield En Face Swept Source OCT Imaging of Retinal Pigment Epithelial Detachment Brian Goldhagen, MD 2:30 Quantitative OCT Angiography of Type 1, 2 and 3 Neovascularization after Anti- VEGF Therapy David Sarraf, MD

5 Session VIII: Macular Neovascularization: Clinical Management Moderator: Jaclyn L. Kovach, MD 2:40 Reasons for Retreatment in CATT and IVAN: Contributions from OCT, Visual Acuity, Angiography, and Dilated Fundus Exam Maureen Maguire, PhD 2:50 Changes in Neovascular Activity Following Continuous Anti-VEGF Administration: 52 Week Results in the VIEW Studies Darius M. Moshfeghi, MD 3:00 The Effect of Switching Drugs in AMD Daniel F. Martin, MD 3:10 The Effect of Switching Anti-VEGF Drugs in DME Frederick L. Ferris, III, MD 3:20 Automation of OCT Report Interpretation- the Future of Monitoring Patients for Disease Activity Anat Loewenstein, MD 3:30 Automated, Remote, Intravitreal Injection: A New Perspective Stephan Michels, MD, MBA Session IX: Macular Neovascularization and Emerging Therapies I Moderator: Zohar Yehoshua, MD, PhD 3:40 Genetic Analysis of VIEW 1 Neovascular AMD Patients Philip J. Rosenfeld, MD, PhD 3:50 A Genetic Analysis of CNV Occurring in CSC and the Pachychoroid Spectrum K. Bailey Freund, MD 4:00 Intravitreal Ziv-Aflibercept for Exudative Macular Diseases Michel E. Farah, MD 4:10 Optimizing Regimen of Neovascular AMD Therapy via Combined PDGF/VEGF Antagonism Pravin U. Dugel, MD 4:20 Aflibercept Combination Therapies: Aflibercept/Anti-ANG 2 and Aflibercept/Anti-PDGF Jeffrey S. Heier, MD

6 4:30 CrossMab Antibody with Dual Inhibition of VEGF-A and Angiopoietin-2 for Exudative AMD and DME Karl G. Csaky, MD, PhD 4:40 Update on Anti-VEGF RTH258 and DARPin for CNV in AMD Lawrence J. Singerman, MD, FACS, FICS Session X: Macular Neovascularization and Emerging Therapies II Moderator: Philip J. Rosenfeld, MD, PhD 4:50 Delivery of the Future: An Update on the Encapsulated Cell Therapy Program Allen C. Ho, MD 5:00 Long-Acting Delivery of Ranibizumab Daniel M. Miller, MD, PhD 5:10 Orally Available Tyrosine Kinase Inhibitor X-82 in Neovascular AMD Philip J. Rosenfeld, MD, PhD 5:20 Topical Squalamine Lactate Ophthalmic Solution for the Treatment of Retinal Disease Jason S. Slakter, MD 5:30 Icon-1 in the Treatment of Neovascular AMD Carl D. Regillo, MD, FACS 5:40 Advances in Gene Therapy for Exudative ARMD Mark S. Blumenkranz, MD 5:50 Gene Transfer of Retinostat, a Lentiviral Vector Expressing Endostatin and Angiostatin, for Neovascular AMD Peter A. Campochiaro, MD 6:00 Adjourn/Cocktail Reception